Stipple Bio vs Saama Analytics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Precision oncology company emerged from stealth Apr 2026 with $100M oversubscribed Series A co-led by RA Capital and a16z Bio; Pointillist platform identifies novel tumor-specific epitopes for antibody-drug conjugates beyond existing ADC targets.
About
Stipple Bio is a precision oncology company that emerged from stealth in April 2026 with a $100 million oversubscribed Series A. The round was co-led by RA Capital Management, Andreessen Horowitz Bio+Health, and Nextech, with additional participation from GV and Emerson Collective — a top-tier syndicate that signals strong scientific conviction in the platform.
Saama Analytics is the #1 AI clinical analytics platform for life sciences; received up to $430M Carlyle-led investment in May 2025; serves 50+ biotech companies across 1,500+ studies including top-20 pharma.
About
Saama Analytics is the leading AI-driven clinical analytics and data management platform for the life sciences industry, positioning itself as the "#1 in AI Clinical Analytics" based on customer adoption across major pharmaceutical and biotechnology companies. Founded and headquartered in the United States, Saama's Life Science Analytics Cloud (LSAC) platform accelerates clinical trial execution by automating data processing, quality checking, safety signal detection, and regulatory submission preparation — tasks that traditionally require significant manual effort from biostatisticians, data managers, and clinical programmers.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.